VTGN
Vistagen Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsLast reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Vistagen Therapeutics, Inc.
Expected move
InputsLast reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Bull1
Bear2
No changes.
No changes.
| Manager | Value | % base | |
|---|---|---|---|
| Commodore Capital | $630,228 | 21.39% | new |
| Vanguardindex-like | $355,769 | 12.07% | 0.00% |
| Two Sigma | $191,646 | 6.50% | +80.57% |
| Acadian | $180,000 | 6.11% | +34.75% |
| Renaissance Technologies | $165,093 | 5.60% | +150.77% |
| Manager | Value | % base | |
|---|---|---|---|
| Commodore Capital | $630,228 | 21.39% | new |
| Vanguardindex-like | $355,769 | 12.07% | 0.00% |
| Two Sigma | $191,646 | 6.50% | +80.57% |
| Acadian | $180,000 | 6.11% | +34.75% |
| Renaissance Technologies | $165,093 | 5.60% | +150.77% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Vistagen Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Vistagen Therapeutics, Inc..
Annual filing, covered
10-K parsed · Jun 15 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Jun 15 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.
Vistagen Therapeutics, Inc.
0.17
−0.01 · −7.76%
Expected move
No implied move.